ARID1A aberrations may lead to differential chromatin accessibility and therefore to blunted anti-cancer directed immune responses, e.g. by reduction of overall IFN-gamma production, diminished immune cell infiltration and insufficient long- term immune memory responses. The gene discussed is ARID1A; the disease is cancer.